A Phase 1 interventional study of Nebivolol and Atenolol in Hypertension, sponsored by Mylan Bertek Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2005-09-12.
Sponsored by Mylan Bertek Pharmaceuticals (part of Viatris Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing nebivolol in Hypertension — none open to participants now, 1 under way, none of them phase 3. Nebivolol · Hypertension.
Among the 58 studies testing nebivolol in Hypertension, this one is the 17th largest by enrollment, is the only one that started in 2003, is one of 2 in phase 1, and was the 4th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 58 studies testing nebivolol in Hypertension is open now. The open studies under Hypertension, anywhere →
Nebivolol: first FDA approval 2007 (BYSTOLIC). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 15 · Phase 4 29
First in 2001; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 70 across the 58 interventional studies. Of the 52 that completed or were terminated, 37 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mylan Bertek Pharmaceuticals, one of the names counted as Viatris Inc.. Under that name alone:
Mylan Bertek Pharmaceuticals is the lead sponsor of 13 studies on the registry; none are open to participants now.
34 studies in Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 34 finished, 11 (32%) have results posted.
Among the 34 studies in Hypertension by Viatris Inc., this one is the 18th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2003, is one of 2 in phase 1, and was the 9th registered.
Viatris Inc.’s Hypertension studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 58 studies testing nebivolol in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 34 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nebivolol is one of a class of drugs known as beta-blockers. These drugs are useful in the treatment of high blood pressure, angina, abnormal heart rhythms and following a heart attack. The purpose of this study is to explore the potential of nebivolol to cause a certain type of abnormal heart rhythm, known as QTc prolongation. The potential of nebivolol to cause this adverse event will be compared to three other drugs: atenolol, a beta-blocker approved by the FDA; Avelox (moxifloxacin), an anti-biotic approved for use by the FDA which is known to cause QTc prolongation; and placebo, a drug look-alike that contains no drug. The working hypothesis was that 20 or 40 mg of nebivolol would not prolong corrected QT intervals measured during peak nebivolol concentrations (i.e., 2 hours after dosing) on Day 7.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Reported or was known to have done the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The primary study endpoint was the change in the average QTc intervals from Day 0 to 2 hours after dosing on Day 7.
The secondary endpoints were the change in average QTc intervals from Day 0 to all other evaluation times and the change in other ECG intervals (PR, RR, QRS, QT) and HR from Day 0 to all other evaluation times.
The record gives a start of Jun 2003 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nebivolol · Atenolol · Moxifloxacin
Mylan Bertek Pharmaceuticals →